L Jason Lobo
Overview
Explore the profile of L Jason Lobo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lobo L, Liu Y, Li P, Ramaswamy M, Swaminathan A, Veeraraghavan S, et al.
BMC Pulm Med
. 2024 Sep;
24(1):468.
PMID: 39334205
Background: To assess the characteristics of patients enrolled in the ILD-PRO Registry. Methods: The ILD-PRO Registry is a multicentre US registry of patients with progressive pulmonary fibrosis. This registry is...
2.
Summer R, Todd J, Neely M, Lobo L, Namen A, Newby L, et al.
Respir Res
. 2024 Jan;
25(1):58.
PMID: 38273290
Background: The circulating metabolome, reflecting underlying cellular processes and disease biology, has not been fully characterized in patients with idiopathic pulmonary fibrosis (IPF). We evaluated whether circulating levels of metabolites...
3.
Doligalski C, McKinzie C, Yang A, Lobo L, Coakley R
Pharmacotherapy
. 2022 Jun;
42(7):580-584.
PMID: 35689451
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is a highly effective therapy for patients with cystic fibrosis (CF) with potential benefits in lung transplant recipients (LTRs) for extrapulmonary CF manifestations; however, tolerability and efficacy in...
4.
Lobo L, Reed K, Wunderink R
Chest
. 2010 Feb;
138(1):130-6.
PMID: 20173050
Background: Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) has been documented to cause community-acquired pneumonias (CAP), notable for necrotizing features. The frequency of occurrence, risk factors, and optimal treatment of CA-MRSA CAP...